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1. Introduction 
 
Fc-receptors play a central role in the regulation of both the efferent and afferent phase of the 
immune response by setting the threshold of B cell activation, regulating DC maturation (1) 
and functioning as a bridge between innate and adaptive immunity (2). Due to the ability of 
immune complexes to bind all types of IgG Fc receptors via the conserved Fc-portion of IgG, 
activating type Fc -receptors (Fc R) may facilitate recruitment and activation of 
inflammatory cells and antigen presentation to effector cells, while the inhibitory Fc RIIb 
may transmit antagonistic signals with a possible outcome of inhibiting cell activation. 
Several previous in vivo studies aimed to examine the nature of this fine balance between 
positive and negative signals with yet controversial results (3) (4).  
Affinities of Fc Rs are variable, low affinity receptors, Fc RII and Fc RIII only bind 
multiple Fc in immune complexes, and are less restricted to the isotype of the antibody, whilst 
the high affinity Fc RI shows a strict preference towards binding monomeric or complexed 
IgG2a (2) (5). 
Activating Fc-receptors share a common consensus immunoreceptor tyrosine based 
activation motif (ITAM) in the intracellular part of the -chain, which becomes 
phosphorylated upon ligand binding, thus forming docking sites for SH2-domain containing 
signalling proteins (6) (7). The only yet described inhibitory receptor of the Fc-receptor 
family is the single chain Fc RIIb, which is widely present on immune cells, though is the 
only classical Fc-receptor expressed on B cells (8). It contains an intracellular 
immunoreceptor tyrosine based inhibitory motif (ITIM), which becomes phosphorylated by 
Src family kinases upon co-ligation of Fc RIIb with activating receptors, such as B-cell 
receptors (BCR) via immune-complexes.  
Several groups reported on the in vivo immuno-modulatory effects of immune-
complexes. IgG1-, IgG2a- and IgG2b-containing complexes can mediate immune response 
with dual outcomes, depending on the type of the antigen. Based on its unique structure, IgG3 
has the capacity to self-associate and activate the complement system, and enhance the 
immune response (9). As IgG-mediated suppression also occurs in mice lacking the known 
Fc Rs, this process is most possibly Fc-receptor independent, and caused by epitope masking 
(10). On the other hand, Fc RIIb-deficient mice respond to immune-complex treatment with 
an up-to 100-fold elevation of the antibody titers (11). Takai et al. demonstrated that mice 
with Fc RIIb deletion are highly susceptible to a more severe form of collagen-induced 
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arthritis, whilst animals lacking the common -chain of the activating Fc-receptors including 
Fc RI and Fc RIII do not develop the disease at all (12) (13).  
As the in vivo data about the regulatory function of immune complexes on the humoral 
immune response are controversial, we carried out a set of experiments where we aimed to 
collect more data about the localisation and in vivo effect of intravenously administered and 
well-characterised immune complexes. Several animal models of inflammatory diseases 
underline the importance of Fc R-function (14) (15, 16) therefore the further understanding 
of the complexity of Fc R-mediated signalling events could highly contribute to the 
development of efficient drugs diminishing inflammation in autoimmune diseases. 
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1.1 Structure of Fc -receptors  
Fc receptors are members of the immunoglobulin superfamily (exception is the C-type lectin 
Fc RII) that bind the Fc part of the immunoglobulin (Ig) molecules, and function as non pre-
determined receptors of the immune complex (IC). Based on their preference towards 
different Ig-isotypes, Fc /μ , Fc , Fc  and Fc receptors have been identified. Depending 
on the structure, single-chain and multi-subunit receptors exist; and on the basis of the 
consensus motifs expressed in the cytoplasmic part, activating and inhibitory receptors are 
known. The affinity of the ligand binding also varies: high affinity Kd=10
-8M, and low affinity 
receptors contribute to the fine-tuning of the immune response. All of the identified classical 
and non-classical Fc-receptors are listed in Table 1 (17) (12).  
 
Based on the structure, multi-subunit and single-chain Fc  receptors exist (Figure 1.) (66) 
(67) (68). The multi-subunit members of the family (Fc RI and Fc RIII) are composed of an 
 chain, which is the subunit responsible for the ligand binding, and at least one signal-
transducing  chain dimer, closely related to the  chain of the T-cell receptor complex that 
contains a highly conserved consensus sequence, the immunoreceptor tyrosine based 
activation motif (ITAM). ITAMs contain two tyrosine residues separated by around 9–12 
amino acids; the canonical ITAM sequence is YXX[L/V]X6–9YXX[L/V] (Y=tyrosine, 
L=leucine, V=valine, and X stands for any amino acid) (18). 
In case of the single-chain receptor Fc RII the ligand recognition domain and the signal-
transmitting sequence are encoded within the same chain, containing either an ITAM or an 
immuno-receptor tyrosine based inhibitory motif (ITIM, [I/V/L/S]XYX2[L/V]) (8), 
depending on the isoform: the human Fc RIIa is an activating receptor, expressed mainly on 
macrophages, neutrophils, eosinophils, platelets and Langerhans cells, while the human 
Fc RIIb1, the main isoform present on B cells and Fc RIIb2 are inhibitory type receptors. 
Due to an additional membrane-proximal sequence  (which is caused by the translation of all 
4 exons of the intracellular chain), the b1 isoform is not internalised, while b2 mediates 
phagocytosis in macrophages, neutrophils and eosinophils (65). In mice, 4 types of Fc  
receptors exist: Fc RI-IV, where Fc RII has inhibitory functions exclusively, Fc RI, III and 
IV have activating functions and Fc RIV resembles homology to the human Fc RIIIa 
isoform. Murine B cells exclusively express Fc RIIb1. (2) 
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While mouse Fc RI (Kd=10
-8M) displays high affinity towards IgG2a isotype specifically 
(it has a low affinity binding capacity for IgG3 as well), Fc RII and Fc RIII bind the IgG Fc 
region with a low affinity (Ka=10
5-106M), but a broader isotype-binding capacity (IgG1, 
IgG2a, and IgG2b). In mice, the most potent effector isotypes are IgG2a and IgG2b; 
involvement of members of the complement cascade in their effector mechanisms has been 
suggested though. 
The recently identified Fc RIV is of intermediate affinity and restricted subclass 
specificity towards IgG2a and IgG2b (5, 19). The receptor is expressed on neutrophils, 
monocytes, macrophages, dendritic cells, mast cells and lymphocytes, and can be up-
regulated upon inflammatory stimuli or TH1 cytokines, while TH2 cytokines or induction of 
cell maturation down-regulate cell surface expression of Fc RIV. 
The pattern of Fc  receptor expression varies on different effector cells so that the isotype 
of the antibody determines which accessory cells are involved in the immune response.  
Figure 1.: Schematic structure of the human Fc-receptors (20) 
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Receptor 
 
Cellular distribution 
Expression in 
mouse/human 
 
Function 
 
Fc RI 
(CD64) 
 
Mo, Ma, Neu, Eo, DC, 
 
m/hu 
ADCC, IC 
phagocytosis, 
oxidative  
burst, cytokine 
release 
 
Fc RIIa 
(CD32A) 
 
Mo, Ma, Eo, Neu, thrombocyte, DC, LC 
 
hu 
 
phagocytosis, 
oxidative burst 
 
Fc RIIb 
(CD32B)  
 
B-cell, mast cell, Ma, Ba, Eo, Neu, DC, 
LC 
 
m/hu 
negative 
regulation of the 
cellular  
response  
 
Fc RIIIa 
(CD16A) 
 
Ma, Mo, NK cell, mast cell, Eo, DC, LC, 
Neu (mouse) 
 
m/hu 
 
phagocytosis, 
ADCC 
 
Fc RIIIb 
(CD16B) 
 
Neu, Eo 
 
hu 
cell activation in 
co-aggregation 
with  
the Fc RIIa 
 
Fc RIV 
 
 
Neu, Mo, Ma, DC 
 
m 
 
phagocytosis 
Fc RI mast cell, Ba, Eo, DC, LC m/hu degranulation 
 
Fc RII 
(CD23) 
 
 
ubiquitous, platelet  
 
m/hu 
 
regulation of IgE 
production 
 
Fc RI 
 
Ma, Neu, Eo 
 
hu 
phagocytosis, 
production of 
free  
radicals, ADCC 
 
FcRn 
 
 
placenta, small intestine, Mo, DC 
 
m/hu 
 
foetal immunity, 
IgG turnover 
Fc ⁄μR B-cell, Ma m/hu not clear 
 
Poly-IgR 
 
 
epithelial cells, liver, small intestine, 
lungs 
 
m/hu 
 
secreted IgA, 
IgM transport 
FcRH1-5 B-cell m/hu not known 
Table 1.: The Fc receptors 
Mo=monocyte, Ma=macrophage, Neu=neutrophil granulocyte, Ba=basophil granulocyte, 
Eo=eosinophil granulocyte, Dc=dendritic cell, NK=natural killer cell, LC=Langerhans-
cell, IC=immune complex, ADCC=Antibody Dependent Cellular Cytotoxicity 
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1.2 The role of Fc -receptors in the regulation of the immune response 
In the course of an infection, early responses are characterised by the activation of the innate 
immune system in order to avoid spreading of the pathogen: on many microbial surfaces (e.g. 
the ones poor in sialic acid), the spontaneously cleaved C3b is bound, and initiates the 
alternative way of complement activation. Surfaces rich in mannose-containing carbohydrates 
facilitate the mannan-binding lectin dependent complement activation pathway - capsular 
polysaccharides induce T-cell independent-2 responses, followed by the production of low 
affinity IgM antibodies, which in turn can initiate the classical way of complement system 
activation. Internalisation of the pathogen may be initiated by complement receptors 
expressed on phagocytotic cells. 
Antigen recognition and uptake also occurs in innate cells via pattern recognition 
receptors (PRRs), like the mannose receptor or scavenger receptors on macrophages (e.g. 
MARCO or CD36), as well as by complement receptors, followed by phagocytosis, cytokine 
release and recruitment of accessory cells (21).  
Fc  receptors play an important role in the regulation of the immune response as they 
represent a link between the innate and adaptive immunity. In the early phase of the immune 
response, IgG3 is the first IgG class produced. The isotype switch is regulated by 
IFN  originating from NK cells and Th1 cells, which induces up-regulation of Fc RI 
expression. In the course of an advanced T cell dependent immune response, as a result of 
Th1 activity, large amounts of affinity-matured IgG2a antibodies are produced (69), high 
affinity ligands for Fc RI. Ligation of Fc RI leads to antigen capturing, internalisation, and 
antigen presentation at least with a 10-fold greater intensity than in the case of the low affinity 
Fc-receptors (22).  
Upon viral infection, the effected cells are usually recognised and destroyed by cytotoxic 
T cells due to viral peptides presented on their MHCI molecules. Viral proteins expressed on 
the cell surface can also be recognised by specific antibodies, so that NK cells can eliminate 
the antibody-coated infected target cells via antibody dependent cellular cytotoxicity (ADCC) 
(70). This process is mediated by the low affinity receptor Fc RIII (CD16), which binds IgG1 
and IgG3, and the outcome is the release of cytoplasmic vesicles containing perforin and 
granzymes destroying the antibody coated cell. 
The most important phagocytotic cells participating in the clearance of invading bacteria 
are neutrophil granulocytes and macrophages. These cells are capable to ingest and destroy 
many pathogens directly, however, ‘labelling’ the cell surface antigens of bacteria (e.g. the 
polysaccharide capsule) with antibodies and/or complement, a process called opsonisation 
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highly enhances the effectiveness of phagocytosis. Macrophages express a whole set of Fc -
receptors on their surface (Fc RI, Fc RIIa, Fc RIIb and Fc RIII). The receptor-mediated 
antigen up-take is followed by lysosomal destruction, and the release of inflammatory 
cytokines like IL-1, IL-6 and TNF  in order to recruit other phagocytotic cells to the site of 
pathogen invasion (71). 
Neutrophils represent the most abundant population of leucocytes in the circulation, and 
they are the earliest cell type mediating an inflammatory response towards invading 
pathogens. Besides the production of reactive oxygen intermediates (ROI), proteolytic 
enzymes and anti-microbial molecules, neutrophils participate in the phagocytosis of the 
pathogens as well. Several different receptors facilitate the antigen recognition: receptors for 
complement cleavage products and pathogen-associated molecular pattern recognition 
receptors, and Fc-receptors. Human neutrophils constitutively express Fc RIIa and 
glycosylphosphatidyl inositol (GPI)-anchored Fc RIIIb, while Fc RI-expression is inducible 
by IFN . Fc RIIIb lacks intracellular signalling domains, it only can trigger cell activation if 
associated with Fc RIIa. On mouse neutrophils though, the ITAM-containing Fc RIIIa and 
the ITIM-containing Fc RIIb are present (72).  
 Distribution of Fc RIIa and Fc RIIb on human dendritic cells (DC) also has a strong 
influence on regulating immunity and tolerance: signalling events mediated by the IIb isoform 
on DCs limit cell maturation and support induction of T cell tolerance, while the activation of 
monocyte derived DCs via Fc RIIa leads to secretion of a set of cytokines like IL-10, IL-6, 
TNF-  and IL-8 (1).  
In the late phase of the humoral immune response, it is essential to down-regulate 
antibody production in order to prevent further tissue damage. When immune complexes 
cross-link the B cell receptor with the Fc RIIb, inhibition of cell activation occurs (73) (74) 
(75). (Molecular mechanisms of this process are described in section 1.5.) Defects at this step 
can lead to autoimmunity due to impaired function of the inhibitory receptor.  
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1.3 The role of IgG-containing ICs in the regulation of the immune response 
In order to maintain the fine balance within the immune system, and avoid excessive or 
ineffective responses towards an antigen, several regulatory mechanisms exist. One of these is 
the co-expression of receptors with similar ligand binding properties but different signalling 
outcomes on the same cell. Fc -receptors share common ligands, however, their preferences 
towards different isotypes vary and they also differ in the signal-transmitting intracellular 
sequence. Therefore, they represent an optimal choice for such a regulatory system. Immune 
complexes have been long described to have regulatory functions, mediating a wide spectrum 
of responses, from the induction of a complete inhibition of antibody production the 
enhancement of the humoral immune response. 
 
The most excessively studied experimental setup to study the IC-mediated modulation of the 
immune response is the injection of erythrocytes as particulate antigens and erythrocyte-
specific IgG in close temporal relationship, where the humoral immune response towards 
erythrocytes is suppressed: either due to the co-cross-linking of BCR and Fc RIIb; induction 
of enhanced phagocytosis and rapid clearance of erythrocytes from the blood by phagocytotic 
cells or masking of the antigen epitope on erythrocytes for B cell recognition (4) (76).  
 Experiments carried out in knock-out mice showed that – in response to erythrocytes as 
particulate antigens, - IgG-mediated suppression is intact by reduced levels of Fc RI 
expression, as well as in the absence of Fc RII and Fc RIII: it occurs most probably via 
epitope-masking (77). 
 On the other hand, administration of ICs composed by monoclonal antibodies and soluble 
antigens enhanced the antigen-specific humoral response, proving that the nature of the 
antigen (particulate vs. soluble) is important concerning the IC-mediated function. The IgG1-, 
IgG2a; and IgG2b-mediated enhancement of antibody synthesis is strongly reduced in -chain 
knock-out animals, while Fc RIIb-deficiency manifests in an overshoot of antibody 
production (78). In the later case, the suggested mechanism is the lack of co-cross-linking by 
ICs. 
Several animal models of IC-mediated disorders, e.g. collagen-induced arthritis, haemolytic 
anaemia or systemic IgG- and IgE-induced anaphylaxis demonstrated that lack of Fc RIIb 
leads to robust effector cell responses and to induction of severe inflammation (3).  
 
Depending on the isotype of the antibody, ICs can mediate maturation of DCs. Ligation of 
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Fc RIIa on immature monocyte-derived DCs induces maturation, increases antigen 
presentation to allogenic T cells, and enhances secretion of many inflammatory cytokines 
including IL-10, IL-6, TNF  and IL-8. Co-ligation of Fc RIIb limits this activation, while 
targeting the inhibitory receptor alone maintains an immature state (1, 5).  
 
 Inflammatory effector cells, like mast cells, macrophages and neutrophil granulocytes 
express both activating and inhibitory type Fc -receptors, thus the cellular response is strictly 
dependent on the isotype of the antibody in IC.  
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1.4 Possible involvement of Fc  receptors in systemic autoimmunity 
Systemic autoimmune diseases are induced by the development of an immune response 
against self-antigens e.g. nuclear proteins from apoptotic cell debris or structures present at an 
immune privileged site of the body. As the antigen cannot be eliminated completely, the 
response remains sustained. Tissue damage occurs due to cytotoxic T cell responses, and 
inappropriate activation of macrophages (e.g. Insulin-dependent diabetes mellitus, Multiple 
Sclerosis, or Autoimmune hemolytic anemia), while the production of low-affinity antibodies 
against these structures results in an excessive formation of immune-complexes that 
contributes to the development of chronic inflammatory conditions (e.g. Systemic lupus 
erythematosus). In special cases of autoimmune responses, antibodies are produced against a 
receptor, and can block or trigger receptor mediated cell activation (e.g. Graves’ disease, 
Myasthenia gravis).  
It is also known that under inflammatory conditions an increase in the ratio of activating 
vs. inhibitory Fc R expression is induced within the effected tissue. Due to their function to 
down-regulate the immune response, a role of Fc -receptors in systemic autoimmunity was 
suggested. The first evidence for their importance in disease onset became obvious as Kleinau 
et al. reported that FcR -chain deficient DBA/1 mice were resistant to collagen induced 
arthritis (CIA), one of the most widely used animal models for rheumatoid arthritis; while the 
Fc RIIb knock out counterparts developed a more severe disease than wild type animals 
[63,64]. Bolland et al. and McGaha et al. showed that both in bone marrow chimeras and in a 
retroviral overexpression systems the correction of Fc RIIb levels mainly on B cells lead to 
the suppression of disease development in autoimmune-prone mice and Fc RIIb deficient 
animals. Surprisingly, the TD response was suppressed, but not the TI; an effect seen on the 
late IgG response, but not on the early IgM production (23).  
The background of the manifestation of autoimmune disorders still remains unknown, 
however, there is a strong association between infection and the onset of disease. Genetic 
background and environmental issues also contribute to the development of autoimmunity.  
Single nucleotide polymorphisms in the human RA and SLE were described in the trans-
membrane part or in the promoter region of Fc RIIb and in the extracellular domain of 
Fc RIIa and Fc RIIIa, depending on the genetic background of the examined population (24) 
(25) (26). The dysfunction of the receptor might lead to the prolonged circulation of the 
immune complexes in the blood and impaired clearance of apoptotic fragments, which results 
in a maintained inflammatory response (27) (28). Also, reduced expression of Fc RIIb on 
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memory and plasmablast cells of SLE patients may result in decreased receptor mediated 
suppression of BCR-induced Ca2+-influx in memory B cells (27). 
According to a new aspect, B cell selection in the germinal center response may depend 
on the relative strength of opposing signals from the BCR and the Fc RIIb. Fc RIIb 
engagement via binding of immune complexes on germinal centre B cells with low affinity 
for antigens, or B cells with potential autoreactivity predominates over BCR engagement of 
antigens in the same immune complexes, thus the cells proceed to apoptosis. High affinity 
antigen-containing complexes on the contrary, inhibit proliferation and apoptosis, enabling 
the progression to memory B cells (29) 
NK cells express predominantly Fc RIIc and Fc RIIIa; the former triggers the lysis of 
antibody-covered target cells and cytokine production, while the latter is mainly responsible 
for antibody dependent cellular cytotoxicity (ADCC). In RA-patients, an allelic 
polymorphism has been reported, which allows the expression of the inhibitory Fc RIIb 
instead of Fc RIIc on NK cells with a higher frequency, thus being able to modulate the 
stimulatory functions of other NK receptors and inhibit NK cell activation (30).  
 
Many therapeutic approaches involve application of antibodies, including truncated or 
genetically modified immunoglobulin molecules like single chain antibody fragments. 
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1.5 Fc receptor mediated signalling pathways 
Similarly to the BCR- and TCR-mediated signalling processes, upon cross-linking of the 
ligand-binding extracellular domains of activating Fc Rs, the ITAM gets phosphorylated by 
members of the src kinase family. In NK cells, Fc RIIIa aggregation leads to the activation of 
leukocyte-specific protein tyrosine kinase (lck), while the Fc RIIa- and Fc RIIIa-mediated 
activation of monocytes and mast cells is followed by lyn and hck phosphorylation .  
Src kinases then phosphorylate the tyrosine residues in the ITAM sequences 
(pYXX[L/V]X6–9pYXX[L/V]), which results in the recruitment and activation of SH2 
domain containing proteins (6), e.g. members of the syk kinase family: ZAP70 in NK cells 
and syk kinase in mast cells and monocytic cells. Activated syk kinases mediate the 
phosphorylation of a number of other proteins, initiating thereby a set of further signalling 
events. 
Due to the activity of the phosphatidyl-inositol-3 kinase (PI-3K), PIP3 gets enriched in 
the cell membrane, and facilitates the recruitment of PH domain containing adaptor 
molecules, e.g. SLP-76 or BLNK (B-cell linker protein). As a next step of downstream 
events, PLC  and Tec kinases (Bruton’s tyrosine kinase, Btk and IL-2 inducible T-cell kinase, 
Itk) are activated, which then leads to the generation of the second messengers inositol-3 
phosphate (IP3) and diacyl-glycerol (DAG), and finally to Ca2+-mobilisation (79). The 
phosphorylation of Tec kinases can also result in the activation of the mitogen-activated 
protein kinase (MAPK) cascade (31).  
Phenotypic changes as a result of small G-protein involvement include cytoskeleton 
rearrangement, degranulation, ADCC and phagocytosis, followed by transcription of cytokine 
genes and inflammatory cytokine release.  
The inhibitory Fc RIIb receptor displays its effect in different ways: (a) upon cross-
linking with an activating receptor, e.g. BCR or Fc RI, the ITIM gets phosphorylated by Lyn 
kinase, and recruits the SH2-domain containing-5-inositol phosphatase 1 (SHIP-1), the SH2-
domain containing tyrosine phosphatase 1, and the adaptor protein Grb2 (Growth factor 
receptor associated binder 2) proximal to the membrane. Lyn then phosphorylates SHIP-1 on 
the NPXY tyrosine, creating thereby a docking site for the PTB domain of the adaptor Dok-1, 
and once this complex is formed, another phosphorylation step on the C-terminal YXLP 
sequence of SHIP-1 occurs. This motif is a binding site of the SH2 domain of SHIP-1 
therefore a competition is initiated between the Fc RIIb and Dok-1 for SHIP-1 binding. A 
mobile heterodimer is formed, which is able to hydrolyse PIP3, and causes the release of 
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several PH domain anchored proteins, like Tec kinases and Akt from the cell membrane, 
which among other processes leads to a reduced Ca2+ signal. SHP-1 mediates the 
dephosphorylation of activated tyrosine kinases, e.g. Syk or Btk. As the SHIP-1/Dok-1 
complex might possess high mobility, Cady et al. hypothesise that it is free to engage in a 
range of different interactions and hydrolyse its substrates (32) (80). SHP-1 on the other hand 
exerts only a local inhibition of signalling. (b) Phosphorylated Dok-1 also binds and activates 
RasGAP, inhibiting thereby the activation of the small G-protein Ras by increasing its 
intrinsically low catalytic activity causing GTP hydrolysis and rapid inactivation. Besides 
Ras, other members of the family of small G-proteins are regulated through the Grb2-pITIM 
interaction e.g. Rho and Rac. As a result of impaired MAPK phosphorylation, the cell cycle 
and the proliferation are affected. (c) The third supposed inhibitory mechanism characteristic 
only for B cells is independent of the ITIM sequence: upon homo-aggregation of the receptor 
a pro-apoptotic signal is generated via the c-Abl-family kinases. All these processes 
contribute to the regulation of cell activation, and the maintenance of a balance in the immune 
response (7, 8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.: Inhibition of antigen receptor mediated signalling events in B cells following 
cross-linking of BCR and Fc RIIb. 
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1.6 Single chain Fragment variable – a useful tool for investigating immune complex 
function 
Single chain Fragment variables (scFv) are genetically modified recombinant antibody 
fragments consisting of the variable regions of the immunoglobulin (Ig) heavy and light 
chains (33). The two immunoglobulin-domains are usually connected by a serine-glycine 
containing linker region, which enables the correct conformation of the antigen-binding 
surface to be established. The specificity and affinity of the scFvs towards the antigen is 
usually equal to the original antibody, however, the avidity is reduced. As the construct lacks 
the Fc-fragment that mediates binding to Fc-receptor expressing cells, it is only the antigen-
specificity of the single chain fragment that directs the protein to the targeted cells (34). 
Therefore, the application of scFvs could be of advantage in many processes including e.g. a 
more successful cellular targeting of drugs to tumour cells, ligating cell surface receptors in 
order to modify co-stimulatory signals or neutralisation of soluble mediators of inflammation 
(35). Due to their small size, they can easily penetrate into tissues, although the specific 
uptake is usually lower, as it was shown with radioactively labelled compounds. The half-life 
of an scFv construct is usually short, and it is filtered out from the circulation within hours. 
This can be modified e.g. with the co-expression of the CL/CH (constant domain of the light 
or the heavy chain) region, with generation of oligomeric complexes, or even with synthetic 
modifications like conjugation of polyethylene glycol chains (PEGylation) to the fragment 
(36). To the contrary, if reduction of the half-life of an antibody drug is necessary, e.g. for 
radioactive targeting, scFv molecules can be ideally used. Single chain Fragment variables, 
like other antibody-derived antigen-recognising molecules can be produced in mg amounts in 
bacterial protein expression systems, e.g. in E. coli cells, even in inclusion bodies or as intact 
periplasmatic proteins. Purification process of inclusion bodies includes several refolding 
steps, but the end product still contains partially refolded or unfolded molecules, and therefore 
offers a surface for aggregation and increases the instability of the protein. The preparations 
are usually contaminated with high levels of lipopolysaccaride (LPS) from bacterial cell wall 
origin.  
Immunogenicity is a major issue regarding to all monoclonal antibody therapies as the 
foreign immunoglobulin is applied in high amounts, and a widespread and repeated 
application is therefore severely limited. Different strategies evolved to avoid the immune 
response that follows the treatment, offering a wide variety of choices from chimeric 
antibodies to transgenic mice. scFv constructs provide several advantages in this aspect as 
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they are less immunogenic due to lack of glycosylation on the variable region, and they can 
easily be modified by humanising the variable region frame sequences (37, 38). 
Recent applications of human monoclonal antibody derived single chain fragments 
include e.g. trials for neutralisation of the influenza virus H5N1 (39), inhibition of T cell 
activation and autoimmune diabetes using a B cell surface-linked CTLA-4 (cytotoxic T-
lymphocyte-associated protein 4) agonist (40), or induction of programmed cell death in 
Her2-expressing tumour cells via targeted delivery of apoptosis inducing factor (41). 
Modeling of immune complexes, as described in the current work, is a specific way of the 
usage of cellular targeting.
(a)    (b) 
 
 
 
 
 
 
 
 
Figure 3.: (a) Schematic representation of an scFv, (b) structural model of the 7G6 scFv 
molecule–established with the RasMol program (figure drawn by Dr. Jozsef Prechl MD, 
PhD). Dark blue represents the VH region, light blue is the VL region, and green colour stands 
for an antigen caught trapped in the antigen-binding groove formed by the two Ig-domains.
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2. Aims of this study were: 
 
• to produce and in vitro characterise an scFv molecule from the mouse CD16/32 
specific clone 2.4G2, 
• to examine the target cells of the recombinant protein in vivo, after intravenous 
injection, 
• to establish a model immune complex from the biotinylated 2.4G2 scFv and FITC, as 
a hapten, 
• to investigate the role of these immune complexes on T-independent and T-dependent 
humoral immune response in vivo, 
• to study whether it is possible to target B cells via the Fc RII by using these immune 
complexes and inhibit their activation (potential therapeutic importance in systemic 
autoimmune disorders). 
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3. Materials and Methods 
 
3.1 Cell culture 
 
All mouse cells were cultured in RPMI 1640 supplemented with 5% foetal calf serum in the 
presence of -mercapto-ethanol (RPMI 1640: 15.36 g/l, NaHCO3: 2 g/l, Na-pyruvate: 110 
mg/l, glutamine: 292 mg/l, -mercaptoetanol: 0.1 M, streptomycin: 50 mg/l, penicillin: 
100000 NE/l, foetal calf serum: 5v/v%) at 37ºC under a 5% CO2 containing atmosphere. 
 
3.2 Mice 
 
C57BL/6 mice at the age of 6-16 weeks were used for all experiments. Previously 
characterised CD16KO animals were a kind gift from Dr. Attila Mocsai. Animals were fed a 
standard diet and tap water ad libitum. Ethical approval was obtained from the local research 
ethic committee. 
 
3.3 PCR synthesis and cloning of the scFv  
 
The rat anti-mouse CD16/CD32 specific clone 2.4G2 was kindly provided by the Department 
of Immunology, University Hospital Utrecht, The Netherlands.  
Cells were cultured under standard conditions in supplemented RPMI 1640 and the 
supernatants were tested for antibody content and specificity. Total RNA was isolated from 
the cells using the Qiagen RNeasy kit and reverse transcription was performed with the 
RevertAidTM M-MuLV Reverse Transcriptase enzyme (Fermentas) using oligo dT primer, 
both according to the manufacturer’s instructions. Immunoglobulin heavy and light chain 
variable sequences were amplified using PCR with the following primers, which already 
contained the Nco I-Not I restriction sites: 
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The thermal cycling profile of the reaction: 
 
94oC 3’    denaturation 
55 oC 2’   annealing 
----------- 
72 oC 30”  
94 oC 30”   30 cycles 
55oC 30” 
----------- 
72 oC 10’ final extension. 
PCR fragments were run in a 1.6% low-melting point agarose gel in TAE buffer (Tris-acetate-
EDTA buffer: 4.84 g/l TRIS.BASE, 2.723 g/l Na-acetate x 3H2O, 0.372 g/l Na2EDTA x 
2H2O) in the presence of 5 μg/ml ethidium-bromide, then isolated and purified with the 
MinElute Gel Extraction Kit (Qiagene), according to the manufacturer’s instructions. In order 
to achieve overlapping regions that encode the linker region of the scFv and secure it’s 
flexibility, the 3’ strand of the light chain and the 5’ strand of the heavy chain sequences had 
to be modified with the following primers: 
 
V 3Link: 5’ AGA GCC ACC TCC GCC TGA ACC GCC TCC ACC TTT GAT TTC CAC 
CTT KGT SC 3’ 
LinkCH : 5’ GGC GGA GGT GGC TCT GGC GGT GGC GGA TCG CAG GTG CAG 
CTG SWG GAG TC 3’ 
The fusion of the two fragments was performed in an overlap-extension step, under the 
following conditions: 
The thermal cycling profile of the reaction: 
 
94oC 3’    denaturation 
57 oC 2’   annealing 
----------- 
72 oC 60”  
94 oC 30”   30 cycles 
55oC 30” 
----------- 
72 oC 10’ final extension 
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The construct was first prepared for cloning as described above, and ligated with T4 DNA 
ligase into an EcoRV linearised pBluescript KS cloning vector. The reaction contained 1μl 
10x buffer, the vector and the purified insert in a 1:5 molar ratio (0.1-0.5 μg each), 0.5 μl 
EcoRV (Fermentas) and 1 μl T4 DNA ligase (Promega), added up with water to 10 μl final 
volume. 100 μl of E. coli DH5  competent cells was thawed on ice and incubated with 5 μl 
ligate for 15 minutes, then placed to 42°C for 45 seconds. Sequentially, 900 μl LB medium 
(10 g trypthon, 5 g yeast extract, 10 g NaCl, 100 μg/ml ampicillin) was added and the cells 
were cultured at 37°C for 30 minutes. Transformed bacteria were then spread to a 40 mg/ml 
X-Gal (5-bromo-4-chloro-3-indolyl- -D-galactopyranoside) and 0.1 mM IPTG containing 
1.5% agar plates. White colonies were picked up and screened by restriction digests, then the 
purified plasmid samples were cut at the NcoI-NotI sites, isolated, and cloned into a linearised 
pET11d vector encoding a hexahistidine-, and a myc-tag at the C-terminal region. The 
intactness of the construct was verified by nucleotide sequencing, the analysis of the 
chromatograms was performed with DNASTAR, and further analysis of the heavy and light 
chain variable region sequences were accomplished by using NCBI-BLAST and the Kabat 
sequence database. 
 
3.4 Purification, refolding and enzymatic biotinylation of the recombinant scFv protein  
 
At the purification and refolding steps the method described by Kurucz et al was applied (42). 
After sequencing, the plasmid construct was transformed into BL21 competent cells, and a 
starter culture was grown overnight at 37°C in 100 μg/ml ampicillin containing LB, with 
constant shaking. The next day, a fresh culture was inoculated at 1:100 dilution and grown at 
37oC until it reached OD600nm=0.6-0.8. Protein expression was then induced by the addition of 
0.5 mM isopropyl -D-1-thiogalactopyranoside (IPTG), a constitutive inducer of the lac 
operon system and cells were cultured for 3 more hours. Bacteria were pelleted, resuspended 
in STE (100 mM Tris-HCl,-2 mM EDTA) at 10ml/g wet pellet, in the presence of 10 mg/ml 
lysozime, and incubated on ice for 30 minutes. After three sonication and washing steps, the 
pellet was solubilised in 50mM Tris-HCl (pH=8) solution containing 2% sodium 
lauroylsarcosin (SLS), then supplied with 10 μM CuSO4, and stirred overnight with a loose 
cap to achive the correct formation of intramolecular disulphide bounds. The next day, urea 
was added to the protein solution at 6 M concentration, and the detergent (SLS) was removed 
with anion exchange DEAE-Sephadex beads. The solution was passed through an equilibrated 
Ni-NTA-agarose column, and the refolding was promoted by washing with buffers containing 
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decreasing urea (6-1 M), and increasing NaCl (0-300 mM) concentrations. Following a 
washing step with a wash buffer (10 mM imidazole, 1% glycerol, 300 mM NaCl and 50 mM 
Tris-HCl pH=8.5), the scFv was eluted from the column (elution buffer: 250 mM imidazole 
300 mM NaCl and 50 mM Tris-HCl pH=8.5).  
Protein constructs containing a fusion peptide-tag recognised by the E.coli biotin protein 
ligase (43) (44) (BirA, Avidity) were biotinylated enzymatically: the refolded 2.4G2 scFv 
(optimal concentration 1mg/ml) was dialysed into 10mM Tris-HCl (pH=8.0), then mixed with 
Biomix A (10x concentration, 0.5 M bicine buffer, pH=8.3) and Biomix B (10x concentration, 
100 mM ATP, 100 mM MgOAc, 500 μM d-biotin), finally, 1μl of BirA was added, and the 
reaction was incubated overnight at RT. The next day the excessive biotin was removed by 
gel filtration chromatography, and the efficiency of biotinylation was analysed with SDS-
PAGE gel electrophoresis and flow cytometry.  
 
 
3.5 SDS-PAGE and dot blots 
 
Protein fractions following Ni+-NTA column based purification or following removal of the 
excessive biotin after the enzymatic reaction were checked for purity and integrity by running 
the samples on a 15% SDS-polyacryl-amide gel, followed by horizontal transfer of the 
proteins at 200 mA constant current for 90 minutes at RT to nitrocellulose membrane or by 
staining with Coomassie Brilliant Blue solution for an hour at RT, where the non-specific 
stain was removed with differentiation buffer in several washing steps thereafter.  
0.5μg of the purified protein 2.4G2 scFv, 7G6 scFv or bovine serum albumin was bound to 
nitrocellulose membrane, then the dot blot was rinsed with TWB-0.05% Tween and blocked 
in 5% milk powder containing wash buffer for an hour at RT. The membrane was then 
incubated for an hour at RT with the c-myc specific primary antibody clone 9E10 (M4439 
Sigma Aldrich) diluted in 5% milk powder at 1 μg/ml concentration. After a 3x5 minutes 
washing step, the secondary antibody (rat anti-mouse IgG1-HRPO, Southern Biotech 1070-
05) was diluted in 1:3000 in blocking buffer and applied under the same conditions. The 
Western blot was developed with the Enhanced Chemiluminescent (ECL) Western Blotting 
Substrate (Pierce) on Medical X-Ray Film General Purpose Blue (MXB, Kodak). 
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Solutions and buffers for SDS-PAGE gel electrophoresis and dot blot analysis: 
 
-10x Tris-glycine electrophoresis buffer 
Tris-HCl       0,25 M 
Glycine       1,92 M 
 
-Running buffer 
10x-es Tris-glycine-buffer   100 ml 
10% SDS       10 ml 
Milli Q water     890 ml 
 
-Resolving gel (15%) 
 
30% acryl-amide/bis-acryl-amide  2.31 ml 
Milli Q water    1.37 ml 
1.5 M Tris-HCl (pH 8.8)  1.25 ml 
10% SDS       50 μl 
10% APS (ammonium-persulphate)    25 μl 
TEMED (tetramethyl-ethylendiamine)2.5 μl 
 
-Stacking gel (4%) 
 
30% acryl-amide/bis-acryl-amide 0.67 ml 
Milli Q water     3.05 ml 
0.5 M Tris-HCl (pH 6.8)  1.25 ml 
10% SDS       50 μl 
10% APS       25 μl 
TEMED          5 μl 
 
 
-2x reducing sample buffer 
 
0.5 M Tris/HCl (pH 6.8)     1 ml 
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10% SDS (Na-dodecyl-sulphate) 1.6 ml 
2-mercapto-ethanol   400 μl 
glycerine    800 μl 
bromo-phenol  blue (10w/v% stock) 200 μl 
 
-Wash buffer (TWB-0.05% Tween-20) 
 
NaCl     80 g/l 
Tris (tris(hydroxi-methyl)-amino-methane)  24.22 g/l 
 Tween-20             500μl/l 
 
3.6 Flow cytometric analysis of the binding characteristics of 2.4G2 scFv 
  
Flow cytometry was performed on the mouse B cell line, A20 and on splenocytes isolated 
from C57Bl/6 mice, respectively. Spleens were removed and treated first with 2 mg/ml 
collagenase D (11088858001, Roche) in collagenase D digestion buffer (10 mM HEPES, 150 
mM NaCl, 5 mM KCl, 1mM MgCl2, 1.8 mM CaCl2, pH=7.4) for 30 minutes at 37˚C, then 
smashed and cell suspensions were haemolysed and filtered with 40μm cell culture strainer 
(BD 352340).  
5*105 A20 cells or splenocytes were washed and resuspended in 100 μl flow buffer (PBS 
supplemented with 1% BSA and 0.1% NaN3), then labelled with 10 μg/ml of biotinylated 
monomeric 2.4G2 scFvs followed by detection with 0.1 μg/ml FITC-conjugated avidin 
(Sigma), or with preformed biotinylated 2.4G2 scFv-avidin-FITC complexes (molar ratio 4:1) 
for 15 minutes on ice. Alternatively, the binding of 2.4G2 scFv was detected by 0.1μg/ml 
streptavidin-Alexa488 (Invitrogene). In some experiments cells were simultaneously stained 
with rat anti-mouse CD45R (B220)-PerCP/Cy5.5, rat anti - mouse CD11b-Alexa 647 
(eBioscience) or anti-mouse CD11c (Serotec), respectively, followed by washing steps with 
1% FCS and 0.01% sodium-azide containing PBS after each staining steps. Samples were 
analysed by flow cytometry (FacsCalibur, Beckton Dickinson), and data were evaluated with 
the winMDI 2.8 software. 
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3.7 Immunisation of mice 
 
Mice were immunised intraperitoneally (i.p.) with 100 μg FITC-dextran (average mol wt 
70000 Da) diluted in 200 μl PBS (T-independent antigen) or 50 μg FITC-conjugated keyhole 
limpet hemocyanine (KLH-FITC) in 100 μl PBS mixed with 50 μl complete Freund’s 
adjuvant/animal (T-dependent antigen) on day 0. Biotinylated 2.4G2 scFv-avidin-FITC (b-
scFv-avidin-FITC) complexes were injected intravenously on day 3 after primary 
immunisation. The complexes were preformed by mixing 60 μg biotinylated 2.4G2 scFv (b-
scFv) with 30 μg avidin-FITC, and incubated at room temperature for 15 minutes. In the case 
of T cell dependent B cell response a second injection of the complexes was performed on 
day 6. Mice were sacrificed 3 days after the last injection and the number of FITC-specific 
cells in the spleen was determined by ELISPOT assay. Statistical analysis of the data was 
performed by GraphPad Prism 4. 
 
3.8 ELISPOT assay measuring FITC-specific antibody producing cells 
 
ELISPOT MultiScreen-HA Filter Plates (Millipore MAHAS4510) were coated with 100 μl 5 
μg/ml FITC-BSA dissolved in PBS overnight at 4ºC, and then the wells were washed three 
times with 200 μl PBS under sterile conditions. Wells were blocked with 200 μl 10% FCS 
containing RPMI 1640 for an hour at 37ºC. Spleens of treated animals were removed, 
smashed and treated with 2ml haemolysis buffer for 1 minute in order to remove red blood 
cells from the cell suspension. After the removal of the blocking solution, 105 or 5*105 
splenocytes/well were seeded to the plates and incubated for 16 hours at 37ºC. The plates 
were then washed three times with PBS, another three times with PBS- 0.05% Tween-20 and 
membrane bound IgM and IgG containing spots were detected with HRP-conjugated rabbit 
anti-mouse IgM and IgG. For the assay-development 10 mg aminoethyl-carbazole (AEC, 
Sigma Aldrich) was dissolved in 1ml of DMF, and filtered after 5 minutes incubation at RT, 
then the filtrate was diluted in 30ml 0.1M sodium-acetate buffer (pH 5.5) and supplemented 
with 15 μl of 30% H2O2. Precipitate formation indicated the site of antigen producing B cells 
on the membrane. Number of spots was evaluated by the C.T.L. ImmunoSpot Professional 
Software Version 4.0 for ELISPOT analysis. 
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3.9 Immunofluorescencent detection of the in vivo localisation of b-2.4G2 scFv-avidin-
FITC complexes 
 
Spleens of b-2.4G2 scFv-avidin-FITC complex treated or FITC-dextran immunised and 
complex-treated animals were taken and mounted in cryostat embedding medium (Killik, Bio-
Optika, Milan, Italy), then stored at –80ºC until being processed. Frozen sections of 8 μm 
thickness were cut, collected and fixed in ice-cold acetone for 5 minutes, then blocked with 
5% BSA in PBS for 30 minutes at RT in wet chamber. Sections were incubated at RT in wet 
chamber for 1h with antibodies specific for mouse c-myc tag (purified at the Department of 
Immunology, Eotvos University), marginal zone macrophage marker (MARCO) (45) or a 
vein endothelial marker recognising antibody IBL-9/2 (46) (both purified at the Department 
of Immunology, Medical University of Pecs), all diluted in blocking buffer at a final 
concentration of 1-5 μg/ml. After 3x 5 minutes washing with PBS, PE-labelled polyclonal 
rabbit anti-rat IgG was used for the detection of the primary antibodies, fluorescent images 
were captured using a ColorView CCD camera mounted onto an Olympus BX61 fluorescent 
microscope. 
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4. Results 
4.1 Cloning of the 2.4G2 IgG light and heavy chain variable region genes, synthesis of 
the scFv construct 
 
The monoclonal rat IgG2b clone 2.4G2 was shown to recognise a common polymorphic 
epitope on the mouse CD16/32 receptors, expressed on a wide range of leucocytes e.g. 
monocytes, macrophages, granulocytes, NK cells, DCs, mast cells, B-lymphocytes and 
CD4 /CD8 /TCR  thymocytes. The aim of this work was to establish a single chain 
Fragment variable construct by cloning the VL and VH sequences of the 2.4G2 antibody, and 
produce the recombinant protein in a bacterial expression system in order to further examine 
the effect of immune complexes on the humoral immune response. 
 2.4G2 hybridoma cells were cultured under standard conditions, then cells were 
collected, and the total RNA was isolated and used for reverse transcription, primed by 
oligodT(18). This cDNA served as a template in the polymerase chain reaction, where we 
obtained a VL fragment of 321 bp and a VH fragment of 363 bp (Figure 4.a).  
 The whole construct was then produced by the fusion of the two fragments (Figure 4.b) 
and the insert was cloned into two differently modified pET11d expression vectors, one of 
them encoding two additional peptide-tags at the C-terminal part of the sequence: a hexa-
histidine tag that facilitated effective purification and refolding, and a c-myc derived peptide 
of 9 amino acids that was used for the detection of the recombinant protein. This vector 
enabled us to produce monomeric scFv, while the other vector also containing a signal 
peptide for the biotin ligase BirA at the N-terminal part was applied for establishing the 
model complexes. Partial in vivo biotinylation of the unfolded protein expressing this tag 
already happens due to the presence of the BirA enzyme in E.coli used for the production of 
the recombinant construct, therefore, we had to work with both of these plasmids in some of 
the experiments.  
 The schematic maps of the final constructs used in this work are shown in Figure 4.c. 
.  
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(a)      (b) 
 
 
 
 
 
 
 
 
 
(c) 
 
 
Figure 4.: After the amplification of the light and heavy chain variable region sequences as 
described in section “Materials and methods”, samples were run on a 1.6% agarose containing 
TAE gel (a). Figure 4. (b) shows the PCR-product after the overlap extension step, where the 
fragment was run in a 1% agarose gel. (c) shows the schematic maps of the scFv construct in 
different pET11d expression vectors.  
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4.2 Nucleic and amino acid sequence analysis of the 2.4G2 scFv construct  
Bacterial colonies were screened via restriction digests, and the clones showing the correct 
restriction patterns were sequenced. Nucleic acid sequences were analysed with Lasergene 
(DNASTAR, Madison, WI, USA) and with an on-line sequence analysis tool ‘The Sequence 
Manipulation Suite’ (www.ualberta.ca/~stothard/javascript, University of Alberta, Canada) 
for open reading frames (Figure 5.).  
The translated amino acid sequences were further compared with the Kabat database of 
immunoglobulin genes. We could identify the essential amino acids in the framework 
sequences including the cysteine residues in positions 23 and 88 in the light chain, and 22 and 
92 in the heavy chain, which are responsible for the intra-molecular disulphide bond 
formation within the immunoglobulin domain. We could also identify the complementarity 
determining regions (CDR1-3, green boxes), thus the cloned sequence corresponded to a 
fusion protein of the rat immunoglobulin light and heavy chain variable regions.  
The blue box on Figure 5. marks the linker region that assures the structural flexibility 
within the two domains. Finally, the sequences were submitted to the NCBI Nucleotide 
Database as a direct submission (GenBank: FJ888350.1 for the light chain, and GenBank: 
FJ888349.1 for the heavy chain). 
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Figure 5.: Nucleic-, and amino acid sequence of the 2.4G2 scFv construct (red boxes indicate 
the cysteine residues essential for disulphide bridge formation, green boxes show the 
complementary determining regions and the blue box highlights the linker region between the 
VL and VH regions). The figure was designed by using ‘The Sequence Manipulation Suite’ 
(www.ualberta.ca/~stothard/javascript). 
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4.3 Production and refolding of the recombinant protein 
The recombinant scFv was purified from bacterial inclusion bodies as described in ‘Materials 
and methods’, and the protein fractions were analysed via SDS-PAGE on a 15% acryl-amide-
bis-acryl-amide gel. The Coomassie Brilliant Blue staining revealed a 35kDa protein, being 
excessively represented in the main fractions 2, 3 and 4 (Figure 5.a), indicating that the 
recombinant protein was successfully purified. 
Samples were also tested for c-myc tag expression: 1μg of BSA, the 2.4G2 scFv or the 
7g6 scFv was bound to nitrocellulose membrane, and the dot blot was developed with a c-myc 
specific primary antibody under standard conditions (Figure 5.b). The majority of our 
experiments required the usage of biotinylated scFv therefore we had to modify the purified 
protein in an additional enzymatic biotinylation step. The effectiveness of this process was 
checked by flow cytometry for every single lot individually. 
 
(a) 
 
(b) 
 
 
 
 
 
 
 
 
 
 
Figure 6.: (a) Fractions of 2.4G2 scFv after purification and refolding on a NiNTA column 
(SDS-PAGE with Coomassie Brilliant Blue staining). 
(b) Dot blot analysis of the purified protein, scFv constructs detected with the c-myc specific 
clone 9E10, and a HRP-conjugated goat anti-mouse IgG-specific secondary antibody 
(chemiluminescent signal on X-ray film).   
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4.4 Biotinylated 2.4G2 scFv (b-2.4G2 scFv) - avidin FITC complexes specifically bind to 
Fc RII/III receptors expressed on A20 mouse B cells or splenocytes in vitro.  
 
Although the epitope recognised by the whole antibody is usually identical to the one 
recognised by the scFv derived from the same clone, first we had to check the functional 
integrity of b-2.4G2 scFv by characterising its binding abilities to different cells.  
A20 mouse B cells were labelled either with the botinylated scFv followed by detection with 
avidin-FITC in a separate step (Figure 7.a, green) or –as we wanted to examine the effect of 
complexes on the immune response-, we also used the preformed complex of the biotinylated 
scFv and avidin-FITC (Figure 7.a, blue). Both procedures verified a significant binding of the 
b-2.4G2 scFv to mouse B cells. 
In another set of experiments we checked whether the scFv construct is able to compete 
with the whole antibody (Figure 7.b., green) for Fc RII binding on A20 cells. The addition of 
excessive unlabelled scFv blocked the binding of the whole antibody to the cell surface 
(Figure 7.b, blue), demonstrating that the construct was functionally intact (baseline signal 
shown in red).  
In vitro binding to splenocytes was assessed by simultaneous labelling of spleen cell 
suspensions for the B cell marker CD19 and for CD16/32 with the biotinylated 2.4G2 scFv, 
detected by avidin-FITC. Similarly to the whole antibody, the scFv also stained the majority 
of CD19 positive cells (Figure 7.c and d, binding of the whole antibody not shown). A 
proportion (4.08%) of CD19- cells corresponding to Fc RII/III-expressing myeloid cells 
represented in the spleen was also labelled by the scFv construct. 
 
Taken together these data suggested that the established b-2.4G2 scFv is specifically 
recognising the mouse CD16/CD32 in vitro, therefore it resulted to be suitable for the further 
in vivo applications. 
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(a)       (b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(c)       (d) 
 
 
 
 
 
 
 
 
Figure 7.: (a) Binding of the biotinylated 2.4G2 scFv to A20 cells, (b) competition 
experiments between the 2.4G2 scFv construct and the whole antibody, (c and d) binding of 
the construct to splenocytes, where cells were co-stained for the B cell marker CD19 within 
the same experiment.  
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4.5 b-2.4G2 scFv-avidin FITC complexes bind to a subset of Fc RII/III receptors 
expressing splenocytes in vivo.  
 
As our aim was to study the regulatory role of well defined immune complexes on the 
antibody production, we prepared preformed b-2.4G2 scFv-avidin-FITC complexes by 
mixing the components at 4:1 molecular ratio and tested the binding to spleen cells of naïve 
C57BL/6 mice in vivo, 15 min and 60 min after intravenous injection. Preliminary data 
indicated that FITC might be internalised, which results in a decreased fluorescent intensity, 
possibly due to low lysosomal pH-values. Therefore, we used the more stable Alexa Fluo488 
dye for this single experiment.  
Following collagenase D treatment of the isolated spleens, we co-stained the samples for 
different subpopulations. Partial binding of the preformed complexes was detected on B220+ 
cells (Figure 8.a), on CD11b+ cells (Figure 8.b), and on CD11c+ cells (Figure 8.c), 
respectively. Although we have tested many different conditions including increasing the 
amount of the injected protein, allowing the complex a longer time to circulate, or preparing 
cell suspensions without collagenase D digest, we could not detect a higher rate of complex 
binding to B cells under any of these conditions.  
As our tests run on blood samples of the treated mice showed no B-cell CD16/32 staining 
in the selected time-points (data not shown), it seemed to be unlikely that the complex would 
not reach the spleen because of being trapped by blood cells. One possible explanation for the 
differences between the in vitro and in vivo data is that the complexes might be filtered out 
from the circulation by the marginal zone within minutes following the injection, thus 
follicular B cells never get into contact with the intact complex. 
 
To confirm the flow cytometric data and gain some further information about the localisation 
of the complex, we went on with the experiments and performed immunofluorescent staining 
on frozen spleen sections of b-2.4G2 scFv-avidin-FITC complex injected animals. 
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(a) 
 
 
(b)      (c) 
 
Figure 8.: In vivo binding of the b-2.4G2 scFv-avidin-FITC complex to (a) B220+, (b) 
CD11bhigh+ and (c) CD11chigh+ splenocytes. Data provided by Zs. Szekeres. 
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4.6 Localisation of the b-2.4G2 scFv-avidin FITC complexes in the spleen 
 
In order to examine the localisation of the complexes in the spleen we injected naïve mice 
intravenously with the 2.4G2-FITC model immune complexes. Thereafter, 8 μm thick frozen 
spleen sections were prepared to see whether the endogenous dye is detectable. Our 
fluorescent images showed that 15 minutes after injection the complex was localised in the 
red pulp of the spleen, but was already partially internalised by marginal zone macrophages. 
60 minutes after injection the signal was trans-located to marginal zone macrophages, and by 
the third hour it was completely diminished, probably due to antigen processing (Figure 9.a). 
We also wanted to check that the fluorescent signal indicates the presence of the whole b-
2.4G2 scFv-avidin-FITC complex rather then the accumulation of avidin-FITC after 
degradation of the complexes. Therefore, we stained sections for the c-myc-tag expressed on 
the scFv as well (Figure 9.b, spleen removed after 15 minutes of injection), and found that the 
signal.is strongly co-localised with the FITC-signal. 
(a) 
      15 min    60 min   3 hours 
(b) 
 
 
Figure 9.: (a) b.2.4G2 scFv-avidin-FITC complexes were injected intravenously to naïve 
C57BL/6 mice, and the spleens were removed 15 minutes, 60 minutes or 3 hours after 
injection. (b) Frozen sections were also stained for c-myc tag expression, 15 minutes 
following injection the complex (green) and the c-myc tag signal (red) co localised in the red 
pulp and the marginal zone (yellow). 
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To further identify the site of binding, we co-stained the sections for several markers 
including B-cell marker B220 and IgM, complement receptors CR1/2, red pulp endothelial 
marker IBL9/2 (Figure 10.a and b) and marginal zone macrophage marker MARCO (Figure 
10.c and d). The b-2.4G2 scFv-avidin-FITC complex was first localised mainly on red pulp 
endothelial cells, then 60 minutes following treatment it was relocated to MARCO+ marginal 
zone macrophages. 
 
 (a)  15 min         (b)         60 min 
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 (c)  15 min         (d)        60 min 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10.: (a) 15 minutes after injection the complex (green) is bound mainly by red pulp 
endothelial cells (red), and a partial binding can be observed in the marginal zone; while 60 
minutes after intravenous treatment the 2.4G2 scFv complex is already mainly localised in the 
marginal zone (b),  as shown by co-staining with the red pulp endothelial cell marker IBL-9/2. 
Co-staining with the marginal zone macrophage marker MARCO 15 minutes (c) or 60 
minutes (d) after injection also supports this observation. 
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4.7 b-2.4G2 scFv - avidin FITC complexes time dependently increase the number of 
FITC-specific antibody forming cells in FITC-dextran immunised mice  
 
We aimed to examine whether the complex formed by b-2.4G2 scFv-avidin FITC has any 
modulatory effect on the humoral immune response, namely, on the FITC-specific antibody 
production. To this object, wild type C57BL/6 animals were immunised with the T-
independent 2 (TI-2) antigen, FITC-dextran to induce a fast and B-cell driven response, then 
the animals were treated with preformed complexes directing the hapten (FITC) to Fc RII and 
Fc RIII positive cells 36, 72 and 108 hours after primer immunisation. The number of 
antibody secreting cells was determined in an enzyme linked immunospot assay (ELISPOT) 
assay on day 6.  
b-2.4G2 scFv-avidin FITC complexes time-dependently enhanced the antigen specific 
humoral response, resulting in a significantly higher proportion of FITC-specific IgM 
producing B cells at the 108 hours time point as compared to animals receiving only avidin-
FITC injection (Figure 11.a). Number of antigen specific IgG producing cells showed a non-
significant increase in this particular experiment (Fig.11.b).  
 
Based on these data, in further experiments we decided to treat the animals with the complex 
on day 3 after primer immunisation. 
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(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11.: Wild type C57BL/6 mice were intraperitoneally immunised with the TI-2 antigen 
FITC-dextran and treated intravenously at different time-points (36h, 72h and 108h after 
primer injection) with avidin-FITC or a pre-formed complex of biotinylated 2.4G2 scFv-
avidin-FITC. Number of FITC-specific IgM (a) and IgG (b) producing B cells was measured 
by enzyme-linked immunospot assay (ELISPOT) on FITC-BSA coated nitrocellulose 
microplates 6 days after first antigen encounter. 
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4.8 The b-2.4G2 scFv-avidin-FITC complexes increase the FITC-specific humoral 
immune response by binding to Fc RII/III in vivo 
 
The recombinant proteins purified from bacterial expression systems contain high amounts of 
bacterial lipopolysaccharide (LPS), which is able to trigger the immune system if injected to 
an animal; independently from the features of the recombinant protein, in our case the 
specificity of the scFv. Therefore, in the next set of experiments we aimed to investigate the 
importance of LPS in the 2.4G2 scFv mediated modulation of the immune response and tried 
to prove that the observed effect is caused by the ligation of CD16/32 rather then by the single 
chain structure.  
Our controls involved groups injected with avidin-FITC and additional LPS at a 
concentration of 1μg/ml ( ), polymyxin B treated recombinant scFv, which supposed to 
neutralise LPS ( ), or usage of another biotinylated scFv-avidin FITC containing complex, 
obtained from the mouse CR1/2 specific clone 7g6 ( ). The site of booster injection was also 
changed; a group of mice was challenged with the complexes intraperitoneally instead of 
intravenous ( ) injection (Figure 12.).  
The results showed that additional LPS did not modulate significantly the response, nor 
did neutralisation of LPS reduce the number of FITC-specific IgM/IgG producing cells. The 
complex formed by 7g6 scFv and avidin FITC did not have any significant influences, either. 
The intraperitoneal booster induced the same effect as the intravenous treatment, namely an 
increment in the antigen-specific antibody response. This indicates the involvement of soluble 
factors in the mechanism, e.g. cytokines besides the role of complex binding APCs. 
 
These data show that Fc RII/III-specific targeting of immune cells has a positive effect on the 
immune response elicited by the TI-2 antigen. 
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(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12.: Receptor specificity of the immune response enhancing effect of biotinylated 
2.4G2 scFv-avidin-FITC complex was investigated via different approaches. (a) shows the 
number of FITC-specific IgM producing cells after treatment with avidin-FITC 
(supplemented with additional LPS at a concentration of 1 μg/ml, ), with the preformed 
complexes of biotinylated CR1/2 specific scFv 7g6-avidin FITC ( ) or biotinylated 2.4G2 
scFv-avidin FITC (with ( ) / without ( ) the LPS neutralising reagent polymyxin B), 
injected i.v. or biotinylated 2.4G2 scFv injected i.p. 4 days post-immunisation with FITC-
dextran. (b) shows the number of FITC-specific IgG producing cells in the same experiment.  
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4.9 The b-2.4G2 scFv-avidin-FITC complexes induce an increased FITC-specific 
humoral immune response both against T-cell independent 2 (TI-2), and T-cell 
dependent (TD) antigen 
 
Based on the structure, antigens can induce different humoral responses. T-cell independent 
antigens are characterised either by their ability to bind to different receptors on the B–cell 
(TI-1), or to activate accessory cells that provide activation and survival signals to the 
effected B cells (TI-2). T-cell dependent (TD) antigens on the other hand require antigen 
processing and presentation, and the presence of antigen specific T helper cells. 
In order to test whether the b-2.4G2 scFv-avidin-FITC complexes have a similar effect on 
TD and TI-2 responses, antibody production of KLH-FITC (TD antigen) immunised mice 
was also studied. A set of different controls including monomeric 2.4G2 scFv and b-2.4G2 
scFv coupled to avidin (tetramer b-2.4G2 scFv) was also involved, to see whether the 
aggregation in the absence of the antigen are contributing to the elevated humoral immune 
response mediated by the complex. 
Mice received the preformed complexes on day 3 after FITC-dextran immunisation and 
on day 3 and day 6 after KLH-FITC immunisation. FITC specific IgM and IgG production 
was monitored on day 6 and day 9 in FITC-dextran and in KLH-FITC immunised mice, 
respectively.  
As shown in Figure 13., the complex caused a significant elevation in the number of 
FITC-specific antibody forming cells both in case of TI-2 and TD antigens. Moreover, 
tetramer biotinylated 2.4G2 scFv-avidin had a similar enhancing effect on the TI-2 but not on 
the TD immune response. KLH-FITC was injected as an aqueous suspension of Freund’s 
adjuvant, causing not only the antigen specific activation of immune cells but also inducing 
inflammation, so the possible cytokine release exerted by the tetramer had no additional effect 
on the TD-response. 
 
We could conclude that the monomeric 2.4G2 scFv is not capable to induce any changes in 
the number of FITC-specific IgM/IgG producing cells, but the aggregation of the protein is 
enough to mediate increased antibody levels in response to the TI-2 antigen FITC-dextran. 
The complex induces elevated antibody responses in both TI-2 and TD-antigen immunsed 
animals. 
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(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
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(c) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(d) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13.: Comparison of the effect of the 2.4G2 scFv on the T cell dependent (TD) and T 
cell independent 2 (TI-2) response of B cells. Mice were immunised with FITC-dextran (TI-2 
antigen) or KLH-FITC (TD antigen), then treated with monomeric or tetrameric 2.4G2 scFv 
or the complex and FITC-specific IgM and IgG producing B cells were detected in an 
ELISPOT assay 3 days after last booster treatment. Number of FITC-specific IgM and IgG 
producing cells was examined both in the FITC-dextran immunised (Figure 13.a and b) and 
KLH-FITC immunised (Figure 13.c and d), tetramer or complex treated groups.  
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4.10 Localisation of the complexes in the spleen following TI-2 and TD immunisation 
 
Next we immunised animals intraperitoneally with a suboptimal dose of FITC-dextran 
(Figure 15.a and b) or KLH-FITC (Figure 15.c and d), and injected them with the preformed 
complexes intravenously on day 3. The signal of the 2.4G2 scFv-avidin-FITC complex was 
detected by fluorescent microscopy. Co-staining with MARCO (red) showed that in 
immunised animals the complex has a localisation similar to that in naïve animals: after 15 
minutes it is already present on marginal zone macrophages, and by 60 minutes it is partially 
internalised, and cleared out from the red pulp. Additionally, in TI-2 immunised animals we 
could observe the presence of the complex on the follicular dendritic cell network 
 
(a)   15min   (b)  60min 
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(c)   15min   (d)  60min 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14.: FITC-dextran (a and b) and KLH-FITC (c and d) immunised animals (n=2/group) 
were treated with the b-2.4G2 scFv-avidin-FITC complex, and spleens were removed 15 or 
60 minutes after i.v. injection. 
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4.11 Elevation of the number of antibody producing cells after treatment with the b-
2.4G2 scFv-avidin-FITC complex requires CD16 (Fc RIII) both in case of TI-2 and TD 
antigen immunised mice 
 
The monoclonal antibody 2.4G2 recognises a determinant expressed on both Fc RIII (CD16) 
and Fc RII (CD32) molecules, raising the question whether the single receptor CD16 knock 
out mice would respond to the b-2.4G2 scFv-avidin-FITC complex treatment similarly to 
their wild type littermates. Therefore, CD16KO C57BL/6 mice were also immunised with TI-
2 or TD antigens then treated with intravenously administered b-2.4G2 scFv-avidin-FITC, 
similarly to the wild type counterparts.  
The lack of CD16 expression caused an enhancement in the IgM response towards FITC-
dextran that could not be further modified by the complex-treatment (Figure 15.a). 
Interestingly though, the IgG-response of these animals towards the antigen was not different 
from the wild type mice, but could not be triggered by the injected complex (Figure 15.b).  
The hapten specific IgM and IgG response in KLH-FITC immunised mice following complex 
treatment was significantly reduced compared to the wild type response (Fig.15c and d). 
 
Taken together, our data suggest that CD16 (Fc RIII), the activating type receptor is mainly 
responsible for the enhanced antibody synthesis under these experimental conditions. 
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(c) 
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Figure 15.: C57BL/6 wt and CD16KO mice were immunised with TI-2 or TD antigens, and 
the number of FITC specific IgM/IgG producing cells was detected in an ELISPOT assay. 
Data provided by Dr. J. Prechl and Zs. Szekeres. 
*: p<0.05, **: p<0.01, ***: p<0.005 control vs. complex, †: p<0.05, ††: p<0.01 wt vs. 
CD16KO) 
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5. Discussion 
Fc-receptors binding monomeric immunoglobulin or ICs have a crucial role in the initiation 
and regulation of normal and pathological immune response. Although this family of proteins 
was described 40 years ago, data about their in vivo function only emerged in the last decade, 
mainly based on studies carried out in knock-out animals.  
 
Antigen presenting cells express a range of Fc Rs, therefore the lack of expression of any of 
these activating or inhibitory receptors has robust effects on the immune response. Fc RI-
deficient mice showed a wide spectrum of defects in Fc-dependent effector cell function: 
reduced endocytosis of IgG, impaired phagocytosis of ICs, defected ADCC reactions, failures 
in the delivery of ICs to antigen presentation pathways, and interestingly, elevated antibody 
responses (47) (20). Fc RIIB knock-out mice spontaneously develop a lupus-like disease 
(48) (49) and had an elevated level of auto-antibodies, while autoimmune prone mouse 
strains express reduced levels of CD32 on activated and GC-B cells. Fc RIIB exerts its 
regulatory function during the late stages of B-cell maturation, preventing the expansion of 
autoreactive B-lymphocytes and their development into plasma cells. In collagen-induced 
arthritis (CIA), a mouse model of rheumatoid arthritis, Fc RIII was critically required in early 
disease onset, while destructive arthritis was developed in the absence of the activating Fc-
receptors CD64/16, most probably due to the activity of Fc RIV (13). Fc /μR, expressed 
mainly on marginal zone B cells, follicular B cells and FDCs, was reported to be a negative 
regulator of humoral immune responses against TI-antigens (50). 
 
During the course of a humoral immune response ICs may engage different types of Fc Rs, 
inducing a complex series of events. Administration of IgG containing ICs in vivo may inhibit 
or enhance antibody production depending on whether activating and/or inhibitory Fc Rs are 
involved in the processes (4). Co-expression of both receptors on the same cell may set a 
threshold for cell activation, while shifting the balanced signalling may lead to the 
development of excessive activation, chronic inflammation or even an autoimmune disease 
(11, 12). To clarify these divergent effects, we aimed to investigate the regulatory function of 
artificial ICs composed of Fc RII/Fc RIII specific biotinylated 2.4G2 scFv and avidin-FITC 
on the FITC-specific humoral immune response.  
In our experiments we intended to apply ICs of defined composition, therefore we produced a 
mono-biotinylated mouse Fc RII/III specific scFv construct from the monoclonal antibody 
2.4G2 that was reported to recognise both Fc RII and Fc RIII, but does not bind to Fc RI or 
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Fc RIV (51), and coupled it to FITC-labelled avidin in a molar ratio of 4:1. FITC as a hapten 
conjugated either to dextran or to KLH was used to trigger T-independent type 2 or T- 
dependent immune response in mice. FITC has several advantages: the dye can usually be 
detected even after several hours of recirculation if injected to animals, furthermore, 
depending on the carrier molecule, it provides a possibility to study the effect of the FITC 
containing ICs either on TI-2 or TD responses specific for the same hapten. Thus we used 
biotin-2.4G2 scFv-avidin-FITC, as a model for ICs that may bind simultaneously both to the 
inhibitory and to the activating Fc Rs and examined their regulatory role upon TI-2 and TD 
responses. 
First, we characterised the binding capacity of the monomeric scFv and the pre-formed 
complex to A20 cells and also to mouse splenocytes in vitro. Single chain antibody fragments 
usually show the same specificity as the whole antibody with a slightly reduced affinity 
towards the antigen epitope they recognise. The assays showed that the antigen recognition 
ability of 2.4G2 scFv was intact, and comparable to the original antibody, moreover, the scFv 
was able to compete with the whole antibody for epitope-binding. 
The in vivo experiments demonstrated that 15 and 60 minutes after intravenous injection the 
2.4G2 scFv-avidin FITC complex bound to a fraction of B220+, CD11b+ and CD11c+ 
splenocytes, corresponding to a small fraction of B cells, macrophages and dendritic cells, 
respectively, as shown by flow cytometry. However, unlike the mouse CR1/2 specific 7G6 
scFv (52), the 2.4G2 scFv containing complexes were filtered out from the circulation and 
degraded within 3 hours. The kinetics of the b-2.4G2 scFv–avidin-FITC treatment has shown 
that it was efficient if added 3 days after the initial immunisation with TI-2 antigen, and since 
we have found that the complex has degraded within 3 hours, these data suggest that the 
2.4G2 scFv complex may exert its effect in the central phase of the immune response, in 
course of the development of antibody forming cells. 
 
Experiments focusing on the delivery of blood-borne pathogens to splenic follicles showed 
that marginal zone B (MZB) cells rapidly capture opsonised antigens e.g. Ficoll via CR1/2, 
and that these cells are dislocated from the marginal zone following LPS or pertussis toxin 
treatment. Others reported that despite of heavy loading of TNP-Ficoll on MZB cells 30 
minutes after injection, the antigen is cleared of surface by 2-3 hours, a process that seems to 
depend on cellular shuttling between the marginal zone and the follicle. Due to the very high 
expression of CR1/2 on the cell surface, FDCs are then thought to successfully compete for 
binding of opsonised antigens in the follicules (53). 
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In order track the localisation of our complexes within the spleen, we used 
immunofluorescent staining of frozen sections. The i.v injected b-2.4G2 scFv-avidin-FITC 
localised first on sinusoid endothelial cells then on marginal zone macrophages, and were 
internalised 60 minutes post injection. By the third hour of observation, neither the FITC 
signal nor the c-myc tag on 2.4G2 scFv could be detected in the spleen. We observed a co-
localisation of FITC signals with MARCO, a marker for marginal zone macrophages. These 
data suggest that the circulating model immune complexes first bind to the Fc Rs on sinusoid 
endothelial cells (54), and then to marginal zone macrophages, whose main function is to take 
up blood borne antigens (55). Marginal zone macrophages express the murine homologue of 
the lectin binding receptor, DC-SIGN, which was recently shown to bind 2,6 sialylated IgG 
(56). The immuncomplexes composed of 2.4G2 scFv and avidin do not contain sialic acid, 
thus bind to Fc RII and Fc RIII but not to the DC-SIGN homologue SIGN-R1 molecules, 
therefore, the uptake of the model complexes seems to be driven by Fc RII/III-mediated 
endocytosis . 
Despite of the relatively high expression of Fc RII on marginal zone B cells (57), the 
complex seemed not to stain the marginal zone B cells nor get through to the follicles within 
the white pulp of the spleen, probably due to the activity of marginal zone macrophages. The 
discrepancies between the data measured by flow cytometry and immunohistochemistry could 
originate from differences in the sensitivity of the two detection methods. 
Localisation of i.v injected b-2.4G2-avidin FITC immune complexes was also studied in mice 
previously immunised with KLH-FITC or dextran-FITC, where we could detect a similar 
binding pattern, namely a co-localisation of the complexes with marginal zone macrophages 
(MARCO+ cells) and with sinusoid endothel cells. In addition, the binding of b-2.4G2 scFv-
avidin-FITC to FDC reticula was also observed in case of the TI-2 response. Rao et al. 
reported that Fc RIIb mRNA and protein levels in GC B cells are down-regulated, as 
compared to non-GC B cells, which indicates that modulation of the B cell response within 
the GCs might not occur through this inhibitory receptor (57). On the other hand, Rao et al 
also found that Fc RIIb was up-regulated on FDC, during the germinal centre response. In 
concert with these findings our data show that the in vivo administered 2.4G2 scFv-avidin-
FITC complexes cannot be detected on B cells, consequently do not regulate through 
Fc RIIb1, but are trapped in the macrophages in the marginal zone and on FDCs, thus may 
regulate via Fc RIIb2 and/or via Fc RIII expressed on these cells. 
The targeted transport of the antigen to the marginal zone macrophages and FDCs resulted in 
an elevated FITC-specific humoral response 6 days after primary immunisation with TI-2 
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antigen. As the scFv had been produced in a bacterial protein expression system, we had to 
rule out the possibility that the detected effect is mediated by bacterial lipopolysaccharid 
(LPS). Neither addition of LPS nor treatment with the LPS neutralizing agent, polymixin B 
modified the level of antibody synthesis, indicating that the enhanced IgM and IgG secretion 
in response to TI-2 antigen induced by the 2.4G2 scFv-avidin-FITC highly depends on 
Fc RII/III. Non-biotinylated, monomeric 2.4G2 scFv molecules in the presence of avidin-
FITC, did not modify antibody synthesis. However, 2.4G2 scFv-tetramers could prime the B 
cell response in an extent comparable to the complex, but only in case of a TI-2 antigen. 
These data indicate that cross-linking of Fc RII/III, thus inducing Fc Rs-mediated activating 
signals is indispensable for the effect. Cell activation via Fc RIII may mediate the release of 
pro-inflammatory cytokines (58), thus we suggest that the enhanced antibody synthesis in 
case of TI-2 antigen and the appearance of IgG isotype could be a result of Fc RIII-induced 
cytokine production, e.g. IL-6, TNF  or IFN  (Figure 16.). In a recent publication, Rittirsch et 
al. report on IC-mediated IL-6- and TNF release in a mouse model of acute lung injury, 
where they demonstrate that the association of TLR4 is essential to proper Fc RIII functions, 
namely to the phosphorylation of the signal-transducing -chain. Our further studies will 
involve local detection of inflammatory cytokine release within the spleen following 
complex-treatment. 
In contrast to the TI-2 response, tetramer scFv 2.4G2 did not modify the B cell response to 
TD antigen. In course of immunisation with the TD antigen KLH-FITC in complete Freund’s 
adjuvant, an appropriate level of cytokines might be synthesised (59) (60), (61), thus 
Fc RII/III cross-linking by the tetramer scFv 2.4G2 has no additional cytokine mediated 
effect.  However, the model complex, b-2.4G2 scFv-avidin-FITC significantly enhanced both 
IgM and IgG production to TD antigen as well compared to the untreated control. This could 
be the result of the formation of larger complexes by binding circulating FITC-specific IgG 
antibodies to avidin-FITC, such a process may enhance antigen presentation and ultimately 
antibody formation. 
The monoclonal antibody 2.4G2 recognises both the activating CD16 and the inhibitory CD32 
receptors, as these proteins show about 90 % sequence homology in their extracellular parts in 
mice. Previous reports have shown that immune complex induced enhancement of bacterial 
antigen presentation requires expression of Fc RIII on DCs (62). Moreover, it was reported 
that immune complex-loaded DCs can prime a T independent response in an Fc RIIb-
dependent manner (63). In order to decide which receptor is responsible for the enhanced 
antibody synthesis, we immunised CD16KO animals with both TI-2 and TD antigen, 
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respectively, and compared their antibody production and its regulation by 2.4G2 scFv-
avidin-FITC complexes with the wild type littermates. CD16KO mice immunised with TI-2 
antigen, dextran-FITC had a slightly higher number of hapten specific IgM producing cells in 
the spleen, but the booster injection with 2.4G2 scFv-FITC complexes did not induce a 
significant elevation of the response. We could not detect significant differences in the 
number of FITC specific IgG producing cells either with or without the i.v. injection of the 
2.4G2 scFv complexes, indicating that the Fc RIII is indispensable for the effect.  
The antibody response to the TD antigen KLH-FITC was also highly significantly enhanced 
by 2.4G2 scFv-avidin FITC complexes in case of wild type animals, which was less 
pronounced in CD16KO mice, indicating that Fc RIII may only partly be responsible for the 
immune complex-induced enhancement of antibody synthesis upon TD response.  
 
Our results demonstrate that ICs, which are able to bind to both Fc RII and Fc RIII, 
preferentially bind to the later in vivo, eventually resulting in an enhanced antibody response.  
 
Figure 16.: Schematic model of the possible act of mechanism 
Taken together these results suggest that immune complexes predominantly act in vivo as 
positive regulators of antibody production, which may be mediated by the induction of 
cytokine synthesis via Fc RIII cross-linking. Immune complexes bound to Fc RII/Fc RIII on 
marginal zone macrophages and dendritic cells may also promote antigen presentation to T 
cells or B cells, thus enhancing antibody synthesis (64). These data also indicate that Fc RIII 
are potential drug target in various immune-mediated diseases.  
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Summary. 
Fc -receptors play an important role in both the afferent and the efferent phase of the immune 
response: while the antigen uptake and presentation is highly facilitated by the activating-type 
Fc -receptors on antigen presenting cells, the inhibitory Fc RIIb is an essential mediator of 
the down-regulation of B cell activation in the late phase.  
In the present work we aimed to further examine the effect of immune complexes on the 
humoral response. Single chain Fragment variables (scFv) represent a widely applied tool for 
cellular targeting as they lack the Fc-part that mediates effector functions. Therefore we 
designed an scFv from the well-characterised clone 2.4G2, specific for the mouse 
CD16/CD32 (Fc RII/Fc RIII). We amplified and isolated the heavy and light chain variable 
regions, cloned them into an expression vector, and in a set of experiments we showed that 
the recombinant protein is intact and recognises the same epitope as the whole antibody. 
For the in vivo studies we prepared a complex of b-2.4G2 scFv-and avidin-FITC in a ratio 4:1 
and injected the complex to naïve C57/BL6 mice to check the localisation of the complex in 
the spleen in various time points. The complex was mainly localised on red pulp endothelial 
cells (IBL 9/2+ cells) by 15 minutes, but got translocated to the MARCO+ marginal zone 
macrophages by 60 minutes, and was completely cleared out of the circulation after 3 hours.  
To characterise the effects of the 2.4G2 scFv on the humoral response, we immunised animals 
with the TI-2 antigen FITC-dextran or the TD antigen KLH-FITC, and injected the mice with 
the complex intravenously as a booster. In ELISPOT assays we analysed the FITC-specific 
antibody responses on day 6 (TI-2 antigen) or day 9 (TD-antigen), and detected a significant 
elevation in the number of IgM and IgG producing cells in the spleen. As the clone 2.4G2 
recognises both the mouse CD16/32, we immunised a group of CD16KO animals to decide 
whether the lack of Fc RIII has any influence on the complex-mediated changes. We found a 
somewhat elevated response to the TI-2 antigen in CD16KO animals that was not altered by 
the complex significantly, while the animals immunised with TD antigen showed a 
significantly reduced response to the complex compared to their wild type littermates.  
Taken together these data indicate that immune complexes predominantly act in vivo as 
positive regulators of antibody production and CD16 is largely responsible for this effect. 
Furthermore, these data suggest that Fc RIII is a potential drug target in various immune-
mediated diseases. 
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Összegzés 
Az Fc -receptorok nagyon fontos szerepet játszanak az immunválaszban, csakúgy az afferens, 
mind az efferens szakaszban: míg az antigén prezentáló sejteken expresszált aktiváló Fc -
receptorok nagyban el segítik az antigén-felvételt és prezentációt, a gátló típusú Fc RIIb a B-
sejt aktiváció gátlásának nagyon fontos közvetít je a kés i fázisban.  
Az itt ismertetett munkával az volt a célunk, hogy megvizsgáljuk az immunkomplexek hatását 
a humorális immunválaszra. Az egyláncú ellenanyagokat (scFv) széles körben használják 
különböz  komplexek adott sejtek való irányítására, mivel nem rendelkeznek az effektor 
funkciókat kiváltó Fc-fragmentummal. Kísérleteink során a jól jellemzett egér CD16/32 
specifikus 2.4G2 klónból egylácú Fv fragmentumot hoztunk létre. Felszaporítottuk és 
izoláltuk a nehéz, és könny  lánc variábilis régiókat, majd ezeket expressziós vektorba 
klónoztuk be, amelynek segítségével scFv fehérjét termeltünk. Kísérleteinkben megmutattuk, 
hogy a rekombináns fehérje intakt, és ugyanazt az epitópot ismeri fel az Fc RII/Fc RIII-on, 
mint a teljes 2.4G2 ellenanyag.  
Az in vivo kísérletekhez a b-2.4G2 scFv és avidin-FITC 4:1 arányú komplexét oltottuk naív 
C57/BL6-os egerekbe, és ellen riztük a komplexek lokalizációját a lépben különböz  
id pontokban. 15 perccel az oltás után a komplexek f leg a vörös pulpa endothel sejtjeinek 
felszínéhez köt dtek (IBL 9/2+ sejtekhez), 60 perc múlva áthelyez dtek a MARCO+ 
marginális zóna makrofágokra, míg 3 óra múlva teljesen kiürült a keringésb l. 
A 2.4G2 scFv humorális válaszra kiváltott hatásának jellemzése érdekében FITC-dextránnal 
(TI-2 antigén), vagy KLH-FITC-cel (TD antigén) immunizált állatokat kezeltük a 
komplexszekkel. ELISPOT módszerrel elemezve a FITC-specifikus ellenanyag választ, a 6. 
(TI-2 antigén) vagy a 9. (TD antigén) napon szignifikáns növekedést tapasztaltunk az IgM és 
IgG termel  lépsejtek számában. Mivel az ellenanyag mindkét receptort (CD16/32) felismeri, 
CD16 génkiütött (KO) egereket is immunizáltunk annak eldöntésére, hogy receptor hiánya 
hatással van-e a komplex-mediált változásokra. A TI-2 antigénnel kezelt állatok esetében a 
CD16KO állatoknál kissé megemelkedett ellenanyag-választ tapasztaltunk, amelyet nem 
befolyásolt  a komplexszel történ  kezelés, míg a TD antigénnel immunizált CD16KO egerek 
komplex-kezelésre adott válasza szignifikánsan alacsonyabb volt a vadtípusú csoporténál.  
Eredményeink azt jelzik, hogy az f ként az Fc RIII tehet  felel ssé a komplexek által 
kiváltott immunválasz serkent  hatásért. 
Összegezve, adataink azt sugallják, hogy az immunkomplexek túlnyomóan pozitív hatással 
vannak az ellenanyagtermelésre in vivo, és hatásukat az Fc RIII (CD16) közvetíti. Így az 
FcgRIII terápiás célpontul szolgálhat számos immunrendszeri betegség kezelése során. 
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